Autolus Therapeutics plc SEC filings AUTL

Autolus Therapeutics plc has 336 filings in SEC EDGAR's recent list, going back to Feb 9, 2018. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
10-K Annual report Mar 27, 2026 Dec 31, 2025
10-K Annual report Mar 20, 2025 Dec 31, 2024
10-K Annual report Mar 21, 2024 Dec 31, 2023
20-F Annual report (foreign issuer) Mar 7, 2023 Dec 31, 2022
20-F Annual report (foreign issuer) Mar 10, 2022 Dec 31, 2021
20-F Annual report (foreign issuer) Mar 4, 2021 Dec 31, 2020
20-F/A Amended annual report (foreign issuer) Jun 30, 2020 Dec 31, 2019
20-F Annual report (foreign issuer) Mar 3, 2020 Dec 31, 2019
20-F Annual report (foreign issuer) Feb 25, 2019 Dec 31, 2018
20-F Annual report (foreign issuer) Nov 23, 2018 Sep 30, 2018

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
AUTL (Nasdaq)
Fiscal year ends
December 31
Incorporated in
United Kingdom
Headquarters
London, United Kingdom
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1730463
Former names
Autolus Therapeutics Ltd (until Jun 8, 2018)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.